KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemed (CHE) Receivables: 2009-2024

Historic Receivables for Chemed (CHE) over the last 16 years, with FY2024 value amounting to $180.0 million.

  • Chemed's Receivables rose 1287.33% to $223.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $223.7 million, marking a year-over-year increase of 1287.33%. This contributed to the annual value of $180.0 million for FY2024, which is 175.9% down from last year.
  • According to the latest figures from FY2024, Chemed's Receivables is $180.0 million, which was down 175.9% from $183.2 million recorded in FY2023.
  • Chemed's Receivables' 5-year high stood at $183.2 million during FY2023, with a 5-year trough of $126.9 million in FY2020.
  • For the 5-year period, Chemed's Receivables averaged around $154.1 million, with its median value being $141.2 million (2022).
  • Per our database at Business Quant, Chemed's Receivables crashed by 1180.17% in 2020 and then surged by 2969.54% in 2023.
  • Annual analysis of 5 years shows Chemed's Receivables stood at $126.9 million in 2020, then grew by 9.66% to $139.1 million in 2021, then grew by 1.53% to $141.2 million in 2022, then increased by 29.7% to $183.2 million in 2023, then fell by 1.76% to $180.0 million in 2024.
  • Its Receivables stands at $180.0 million for FY2024, versus $183.2 million for FY2023 and $141.2 million for FY2022.